Brief: SynAct Pharma Q2 Net Income at SEK -43.511 Million
04/08/2023 06:34
Aug 4 (Reuters) - SynAct Pharma Q2 adjusted EPS SEK -1.37. * Q2 cash flow from operating activities SEK -34.657 million * Q2 sales SEK 0 * Q2 net income SEK -43.511 million * Q2 operating expenses SEK 43.495 million
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development